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CD40CD40L interaction is essential for multiple biological events
in T dependent humoral immune responses, including B cell sur-
vival and proliferation, germinal center and memory B cell forma-
tion, and antibody isotype switching and affinity maturation. By
using high-density microarrays, we examined gene expression in
primary mouse B lymphocytes after multiple time points of CD40L
stimulation. In addition to genes involved in cell survival and
growth, which are also induced by other mitogens such as lipo-
polysaccharide, CD40L specifically activated genes involved in
germinal center formation and T cell costimulatory molecules that
facilitate T dependent humoral immunity. Next, by examining the
roles of individual CD40-activated signal transduction pathways,
we dissected the overall CD40-mediated response into genes
independently regulated by the individual pathways or collectively
by all pathways. We also found that gene down-regulation is a
significant part of the overall response and that the p38 pathway
plays an important role in this process, whereas the NF-B pathway
is important for the up-regulation of primary response genes. Our
finding of overlapping independent control of gene expression
modules by different pathways suggests, in principle, that distinct
biological behaviors that depend on distinct gene expression
subsets can be manipulated by targeting specific signaling
pathways.
CD40 is a member of the pleiotropic tumor necrosis factorreceptor (TNFR) superfamily, which also includes such
functionally diverse molecules as CD27, CD30, OX40, RANK,
LT-R, the p75 low-affinity nerve growth factor receptor, Fas,
and members of the death receptor family as well as TNFR1 and
TNFR2 (1). CD40 stimulation activates B cells and promotes
various aspects of a functional humoral immune response,
including enhancement of survival and proliferation (2). Like
many TNFR family members, CD40 activates the JNKSAPK
and NF-B pathways (3, 4). Both of these pathways involve
serinethreonine kinases that regulate gene expression through
activation of AP1 and Rel transcription factors, respectively.
Another stress-responsive pathway that has also been reported
to be activated by CD40 (5) is the p38 kinase pathway, which
leads to the phosphorylation and activation of transcription
factors such as ATF2 (6). Previous work has also linked CD40
to the activation of the extracellular signal-regulated kinase
(ERK)mitogen-activated protein kinase (MAPK) pathway (7).
In addition to serinethreonine kinases, a link between CD40
signaling and tyrosine kinase activation has been suggested (8).
One pathway shown to be activated by CD40 and to play an
important role in CD40 signaling is that initiated by PI-3 kinase
(PI-3K) (8–10). PI-3K phosphorylates membrane phospholipids
(11), which can recruit and activate pleckstrin homology domain-
containing molecules such as the kinase protein kinase B. This
kinase may then regulate the activity of forkhead-related tran-
scription factors (12, 13).
In each of the above pathways, one of the major final outcomes
is an alteration in the activity of one or more transcription
factors, and hence it is generally believed that CD40 achieves
many of its complex effects on B cells through alterations in gene
expression. CD40 up-regulates expression of numerous genes,
including CD23, intercellular adhesion molecule-1 (ICAM-1),
Fas, B7.1, B7.2, MHC II, LT-, c-myc, Bcl-x, Bfl-1, A20, CDK4,
CDK6, IgC, and IgC (2, 14–21). From the standpoint of
signaling specificity, it is not presently clear which (if any)
CD40-mediated gene expression responses are specific to CD40,
as a B cell costimulus, and which are less specific manifestations
of mitogenic B cell activation. Also, the nature of the cooper-
ation between different CD40-mediated signaling pathways in
the overall gene expression response has not been defined. For
this purpose, gene expression profiling can be used to measure
the relative impact of each pathway in CD40-mediated B cell
activation and to examine the nature of that impact. With these
goals in mind, we have undertaken a controlled and systematic
screen for CD40-mediated gene expression in B cells and have
dissected the contributions of multiple CD40-activated signaling
pathways to early gene expression through the use of high-
density oligonucleotide microarrays.
Materials and Methods
Primary B Cell Isolation and Culture. Spleens were isolated from 8-
to 10-week-old C57BL6J mice (The Jackson Laboratory).
Splenic T cells were removed by incubating with monoclonal
anti-Thy1.2 IgM (Sigma) followed by lysis with rabbit comple-
ment (Cedarlane Laboratories). At this step, the cells were
typically 95% pure B220 B cells by FACS analysis. To obtain
highly pure naı¨ve B cells for microarray studies, these cells were
stained with a biotin-conjugated anti-CD43 antibody (Phar-
Mingen) followed by streptavidin-conjugated magnetic mi-
crobeads (Miltenyi Biotec, Auburn, CA) and passed through a
depletion-type magnetic sorting column (Miltenyi Biotec). Un-
bound cells were collected as the purified resting B cell sample—
over 98% pure B220 B cells expressing low levels of activation
markers such as ICAM-1, CD23, and B7.2 by FACS analysis
(data not shown). B cells were cultured in RPMI media 1640
supplemented with 10% FBS, 50 M -mercaptoethanol, and
1% penicillinstreptomycin (Life Technologies, Rockville, MD)
at 37°C under 10% CO2. Cells were stimulated with soluble
CD8CD40L fusion at 300 ngml or lipopolysaccharide at 20
Abbreviations: MAPK, mitogen-activated protein kinase; PI-3K, PI-3 kinase; ICAM-1, inter-
cellular adhesion molecule-1; CHX, cycloheximide; ERK, extracellular signal-regulated
kinase.
¶To whom reprint requests should be addressed at: Department of Microbiology and
Molecular Genetics, Jonsson Comprehensive Cancer Center, and Molecular Biology Insti-
tute, University of California, Los Angeles, CA 90095. E-mail: genhongc@microbio.
ucla.edu.
The publication costs of this article were defrayed in part by page charge payment. This
article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C.
§1734 solely to indicate this fact.
www.pnas.orgcgidoi10.1073pnas.032665099 PNAS  February 5, 2002  vol. 99  no. 3  1497–1502
IM
M
U
N
O
LO
G
Y
gml unless otherwise indicated. Cells stimulated for microar-
ray analysis were cultured at 2.5  106 cellsml.
Measurement of Cellular Proliferation and Apoptosis. For prolifer-
ation assays, B cells were stimulated at 5.0  105 cellsml in
96-well plates for 42 h, pulsed with 0.5 Ci 3H-thymidine per
well, incubated for an additional 6 h, and collected on a 96-well
filtermat by using an automated harvester. Activity was mea-
sured in a 96-well format on a scintillation counter. Cell death
was measured through FACS analysis after 24 h of culture by
double staining with propidium iodide and FITC-conjugated
anti-Annexin V antibody. The percentage of cells in the double-
negative quadrant was recorded as the viable fraction.
Target Preparation and Microarray Analysis. Primary B cells were
flash frozen in liquid nitrogen after stimulation for 2 h with or
without soluble CD40L in the presence of DMSO (0.1%), U0126
(10 M), SB203580 (10 M), or LY294002 (10 M), or for
variable lengths of time in the presence of CD40L (300 ngml)
alone or lipopolysaccharide (20 gml) alone or in media. Total
and poly(A) RNA were isolated by using commercially avail-
able kits (Qiagen, Chatsworth, CA) with a typical yield of 5–10
g total and 0.5–1.0 g of poly(A) RNA per condition.
Synthesis of cDNA was carried out by using a T7-oligo-dT primer
(Gensent, La Jolla, CA) with Superscript-II RT and related
reagents (GIBCO). In vitro transcription of biotin-labeled cRNA
was carried out by using a commercially available kit (Enzo
Diagnostics). Yield of cRNA typically ranged from 40 to 80 g
per condition.
Mu6500 expression probe arrays (Affymetrix) were used for
expression screening. Hybridization was carried out at 45°C for
16 h under constant rotation. After washing and staining, chips
were scanned by using an argon–ion laser scanner (Hewlett–
Packard) at a wavelength of 570 nM. Gene expression results
were captured, normalized through global scaling, and analyzed
by using GENECHIP analysis software (Affymetrix).
Hierarchical Clustering. Determination of gene induction, inhibi-
tion, and pathway dependence was based on multiple GENECHIP
parameters, including fold change and average difference
change, as explained in detail in the supporting information on
the PNAS web site, www.pnas.org. Hierarchical clustering was
performed by using publicly available software (http:
rana.stanford.edusoftware). Single-axis clustering of average
difference change values (Fig. 2) and bidirectional clustering of
pathway dependence profiles (Fig. 3) were performed through
average linkage clustering by using an uncentered Pearson’s
correlation coefficient as the similarity metric.
Results
The Roles of Multiple Pathways in CD40-Mediated Survival and
Proliferation. Survival and proliferation are two well-known
responses of B cells to CD40 activation. Much remains to be
learned, however, about the specific signaling pathways and
downstream gene expression responses responsible for such
fundamental biological effects. As a functional measure of CD40
signaling in B cells, we examined the ability of CD40L to protect
cultured primary B cells from spontaneous apoptosis and to
promote proliferation in the presence of different pathway
inhibitors. As shown in Fig. 1A, CD40 continues to promote
survival in B cells in the presence of pharmacological inhibitors
of the ERK, p38, or PI-3K pathways. Although blocking ERK
activation or PI-3K function does produce some reduction in the
viable percentage, there is still a significant response to CD40
stimulation compared with baseline.
In contrast to the survival response, B cell proliferation is
extremely sensitive to all of the conditions examined. As shown
in Fig. 1B, each pathway inhibitor diminishes the proliferative
response down to near-basal levels. Because proliferation is a
complex process requiring the cooperation of multiple func-
tional classes of genes at many levels, it is likely to be sensitive
to biochemical perturbations within any one of numerous sig-
naling pathways.
Genes with Roles in Adhesion, Migration, and Lymphoid Organization
Are Induced in a CD40-Specific Manner. To examine the evolution of
B cell responses to CD40 stimulation over an extended time
course, we stimulated primary B cells with soluble CD40L for 4,
12, 24, or 72 h or 1 week in culture. We then examined gene
expression profiles by using microarrays representing 6,350
murine sequences. Clustering was performed to distinguish
genes based on temporal expression patterns (see supporting
information on the PNAS web site).
Because many of the effects of CD40 stimulation on B cells
may be common to a number of mitogenic stimuli, we differ-
entiated CD40-specific responses from general mitogenic effects
through a comparative analysis by using another potent B cell
mitogen, lipopolysaccharide, as a control. As summarized in Fig.
2, many of the CD40-specific genes identified in this fashion were
genes with roles in cellular adhesion, migration, and lymphoid
organization. Both lymphotoxin- and -, which together play an
indispensable role in dendritic cell recruitment and germinal
center formation (22, 23), were induced specifically by CD40.
Other CD40-induced genes with potentially important roles in
cellular recruitment and interaction within sites of B cell acti-
vation are the receptor for macrophage inflammatory protein-1
and properdin. The latter is a C3-convertase stabilizer that
functions in the activation of the alternative complement path-
Fig. 1. Contribution of multiple pathways is required for CD40-mediated
proliferation but not survival signaling. (A) Charts display the percentage of
viable B cells (as measured by FACS analysis after propidium iodide-annexin V
staining) after CD40L stimulation with or without various pharmacological
inhibitors. (B) Charts display the level of proliferation of CD40L-stimulated B
cells (as measured by incorporation of 3H-labeled thymidine) with or without
various pharmacological inhibitors.
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way, potentially leading to localized release of chemotactic
complement products. In addition, CD40 induces the expression
of OX40 ligand and 4–1BB ligand, two members of the tumor
necrosis factor family with important roles in the activation of T
cells and in their recruitment to lymphoid follicles (24, 25). Also
included in Fig. 2 are integrin -7 and the extracellular matrix
protein entactin. The role of integrins in leukocyte adhesion and
homing is well established. Entactin is known to play important
roles in adhesion and migration in other systems (26), although
its role in B cell biology has not been established. Interestingly,
the CD40-specific induction of Wnt-10a, a recently characterized
member of the Wnt family, LEF-1S, a transcriptional mediator
of Wnt-activated responses and the Disheveled signaling mole-
cule (not shown), suggests a novel potential connection between
CD40-mediated B cell activation and Wnt signaling.
Multipathway Dissection of the CD40-Regulated Expression Response.
We next examined the contributions of the PI-3 kinase, p38
kinase, and ERK pathways to early CD40-mediated gene regu-
lation by using pharmacological inhibitors to block each signal
individually during stimulation. Because there are five NF-B
subunits with roles in transcriptional regulation, mice with a
complete defect in all subunits are not currently available. Thus,
we examined CD40-regulated gene expression in B cells from
mice bearing homozygous mutations in both the p50 and c-Rel
genes—both of which play important roles in lymphocyte acti-
vation (27, 28)—and a heterozygous mutation at the p65 locus.
These compound mutants, NF-B-2.5 knockout mice, represent
the most severe defect in lymphocyte-mediated NF-B signaling
currently available in a viable animal.
To distinguish primary responses from secondary ones (i.e.,
those that depend on new protein synthesis), stimulation was also
performed in the presence of the protein synthesis inhibitor
cycloheximide (CHX). We found that 30 of 86 CD40L-induced
genes were induced in the presence of CHX, and 52 of 128
CD40L-inhibited genes were inhibited in the presence of CHX
(see supporting information on the PNAS web site). Many of the
protein synthesis-independent gene induction responses are
genes previously reported to be targets of NF-B signaling,
including Bcl-x, A1, TRAF1, ICAM-1, A20, c-myc, IL-1, and
IB- (16, 21, 29, 30), which suggests that this pathway domi-
nates the primary response to CD40L. Indeed, many of the other
CHX-insensitive induced genes, such as the cytokine EBI3, the
putative G protein-coupled receptor TDAG8, and the adhesion
receptor CD83, may also prove to be regulated by the NF-B
pathway.
Over half of the genes inhibited by CD40 stimulation appear
to require new protein synthesis for their down-regulation. The
down-regulation of many transcription factors (e.g., IRF2,
NIP45, and Fli-1), potential growth repressors (SPA-1, Rb2
p130), and kinases involved in MAPK pathways, however,
appears CHX-insensitive. Thus, the number of genes regulated
and the percentage of those genes likely to represent primary
responses are similar for CD40-induced and -inhibited genes.
The results from all pathways tested were then pooled together
and hierarchically clustered, and in Fig. 3, we focus on repre-
sentative clusters of CD40-induced and -inhibited genes. Among
both CD40-induced and -inhibited genes, there are groups of
genes whose regulation does not depend on any of the pathways
tested (core response genes). A large fraction of the genes
display the opposite behavior in terms of pathway dependence—
they depend on most or all pathways tested (collective control
genes). Finally, there are a number of genes whose regulation
depends on a single pathway or a combination of two pathways
(independent control genes).
NF-B-2.5 Knockout. The induction of a number of genes was
found to be sensitive to this partial NF-B deficiency. As
expected, many of these genes are also CHX-insensitive; how-
ever, many of the primary response genes previously associated
with the NF-B pathway (e.g., Bcl-x, A1, ICAM-1, A20, etc.) are
not affected. Indeed, the effect of this compound mutation on
CD40-mediated B cell activation was far less severe than initially
expected, and possible reasons for this are discussed below.
Although this is not a complete mutation of all NF-B family
members, these results do indicate that many of the most highly
induced CD40-responsive genes in B cells do not require either
p50 or c-Rel for their induction.
By the same token, the NF-B targets c-myc and IL-1 and
many other CD40-induced genes were found to require one or
both of these subunits (or perhaps a higher dose of the p65 gene)
for their induction. These genes included the primary response
gene EBI3, a cytokine homologous to the p40 subunit of IL-12
(31). They also included TDAG8, a putative G protein-coupled
receptor in the same family as G2A, a recently cloned receptor
with a potential role in cell cycle arrest (32). Also affected were
the potential secondary response genes complement receptor 2,
STAT-5a, and the mysterious nuclear molecule Jumonji, which
plays an important role in development and may be a growth
inhibitor (33).
ERK Pathway. In addition to clustering genes according to their
pathway dependence, individual treatment conditions were also
clustered according to the genes whose regulation they affected.
In general, most gene regulation is not affected by U0126,
suggesting that early CD40-mediated responses are largely in-
Fig. 2. CD40-specific genes include numerous mediators of lymphoid traf-
ficking and communication. (A) Hierarchical clustering was performed to
distinguish stimulus-specific gene clusters. Shown are representative early
(Top) and middle and late (Bottom) CD40-specific clusters. (B) Examples of
CD40-specific genes with potential roles in immune cell trafficking and
communication.
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dependent of the ERK pathway. For this reason, the U0126
condition forms an outgroup in the tree shown in Fig. 3A.
Indeed, when clustering is performed according to overall gene
expression patterns among the different arrays tested, expression
profiles from CD40L-treated cells in the presence of U0126 are
closest to those from control CD40L-treated cells (data not
shown).
PI-3K Pathway. When clustering according to induced genes,
LY294002 (a PI-3K blocker), and CHX are grouped together. As
demonstrated in Fig. 3A, this is largely because many of the
independent control genes corresponding to the PI-3K pathway
are also CHX-sensitive. These include various transporters and
enzymes involved in metabolic processes (e.g., monocarboxylate
transporter, reduced folate carrier, Ca2 ATPase 2, alkaline
phosphatase, sialyltransferase 10, etc.). This result suggests one
of the roles of this pathway in CD40 biology may be up-
regulation of metabolic mediators needed by the activated and
growing cell. Roughly balancing the role of PI-3K in gene
induction is its role in gene inhibition. It is required for the
down-regulation of transcription factors, such as LKLF, TSC-22,
N-Oct3, NIP45, ZFP-90, and IRF-2, as well as adhesion recep-
tors such as L-selectin and integrin-6.
p38 Pathway. Clustering of pathways based on down-regulated
genes produces a different arrangement. The major outgroup in
Fig. 3B is SB203580 (a p38 inhibitor), because this pathway
appears to play the most prominent role in gene inhibition. The
p38 pathway is distinguished from the other pathways in this
regard by a group of independent control genes, almost all
CHX-insensitive, whose down-regulation is prevented only when
the p38 pathway is blocked. The majority of all primary CD40-
inhibited genes require this pathway for their down-regulation
These include, among other genes, a number of detoxification
stress response genes such as catalase, glutathione peroxidase,
and aldehyde dehydrogenase. Also included are several MAPK
pathway components such as ERK, MEKK3, and p38 itself,
possibly representing a mechanism for collective negative feed-
back on MAPK pathways.
Discussion
Through a systematic screen for CD40-regulated gene expres-
sion, we identified a large number of previously unrecognized
CD40 targets with various biological roles. These are primary as
well as secondary response genes and include transcription
factors, cytokines, receptors, signaling molecules, proapoptotic
molecules, regulators of proliferation, and metabolic mediators.
Many CD40-specific genes represent potential mediators of
germinal center formation in T dependent immune responses,
distinguishing CD40 from lipopolysaccharide, a T independent
activator. It is within germinal centers that events critical to
affinity maturation and memory, two hallmarks of T dependent
immunity, take place. CD40 and CD40L are required for the
formation of these lymphoid structures (34). Furthermore,
the recruitment of follicular dendritic cells (a prerequisite for the
formation of germinal centers) depends on B cells. Lymphotoxin
expression is instrumental in this role of B cells (22, 23). We find
that both LT- and - (together forming the functional ligand for
LT-R) are induced in a CD40-specific manner. In addition, a
number of other candidate molecules with roles in chemoattrac-
tion, cellular adhesion, and migration are induced by CD40.
These molecules also may play roles in various steps of this
complex process. Our data suggest that a distinct signal activated
only by CD40 is required for the induction of lymphotoxins and
other candidate germinal center-promoting genes. In support of
this notion, it was recently demonstrated in vivo that LMP1, an
Epstein–Barr virus-encoded protein thought to signal through
similar pathways, can rescue some but not all CD40-mediated
functions in CD40 animals (35). Specifically, it was found
that germinal center formation was not rescued by LMP1.
A large number of mRNAs are decreased after CD40 stimu-
lation. Other studies comparing the gene expression responses of
Fig. 3. Differential requirements for various CD40-activated signaling pathways in gene induction and inhibition. Dependence of gene inductioninhibition
on multiple pathways and on new protein synthesis (CHX) was determined as described in Materials and Methods, and the results were hierarchically clustered.
Inhibited pathways: p50:c-Rel:p65 (B 2.5-KO), ERK (U0126), p38 (SB203580), and PI-3K (LY294002). Closeups of representative clusters of (A)
induced and (B) inhibited genes are shown. Gold squares represent genes whose inductioninhibition by CD40L is independent of a given pathway (e.g., not
blocked by addition of drug). Blue squares represent genes that depend on a given pathway, and black squares represent genes that did not meet criteria for
classification as either independent or dependent.
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B cells to tolerizing vs. activating antigen found that foreign
stimulation led to a similar down-regulation profile (36). The
large number of transcriptional regulators (18 total) that are
down-regulated, many of them transcriptional repressors, sug-
gests that gene inhibition contributes to CD40-regulated tran-
scriptional reprogramming, for instance, by releasing other
genes from transcriptional repression. Several genes whose
expression in cells has been shown to lead to cell cycle arrest,
including Rb-1, Rb-2, SLAP, BTG-2, and SPA-1 (37–40), were
also down-regulated. This may also be a mechanism for releasing
resting B cells from quiescence. Finally, a number of kinases
associated with B cell activation (e.g., p38, ERK, and BTK) were
also down-regulated, suggesting a mechanism for feedback reg-
ulation of such pathways.
Among induced genes, the core response group includes a
number of previously characterized NF-B targets, including
ICAM-1, TRAF1, Bcl-x, A1, and A20 (16, 21, 29, 30). The
compound mutant animals used to test the role of this pathway
(p50, c-Rel, p65) are not completely deficient in
NF-B activity. This result indicates that in the induction of these
genes, but not in the induction of genes such as c-myc, IL-1,
TDAG8, and EBI3, other NF-B subunits or other pathways are
able to compensate. In support of the view that most of these
core response genes are indeed NF-B targets, we have found
that the induction of these genes is blocked in the presence of
molecules such as gliotoxin and SN-50, which block all NF-B
activity (data not shown).
Like the NF-B pathway, the PI-3K pathway makes a major
contribution to gene induction by CD40. Although many of the
genes that depend on NF-B were primary response genes, the
majority of PI-3K-dependent genes are secondary response
genes. These include a number of metabolic enzymes and
transporters. Although previous work has reported a link be-
tween PI-3K and the NF-B pathway (41–43), we find in our
system that inhibition of PI-3K does not interfere with the
induction of many NF-B-regulated genes. In addition, we find
that in primary B cells, inhibiting PI-3K through the use of
LY294002 does not reduce CD40-mediated NF-B activation as
measured by electrophoretic mobility-shift assay (data not
shown).
The role of the p38 pathway in gene induction appears to be
smaller than that of the other two pathways and almost entirely
cooperative (i.e., also requiring other pathways). Interestingly,
however, this pathway appears to play a major role in CD40-
mediated gene down-regulation. A significant portion of this role
appears to be independent (i.e., not involving any of the other
pathways tested) and primary in nature. Over half of the genes
inhibited in a CHX-insensitive manner require this pathway, and
many of the rest were core response genes not affected by any
of the pathways tested. The mechanism through which p38
achieves this effect is of great interest as it represents a poten-
tially novel mechanism contributing to CD40 biology. One
mechanism may be through transcriptional repression. Although
the mediator(s) of such repression is unclear, studies on the
regulation of insulin, cyclin D2, and retinoid-X receptor (44–46)
have revealed enhanced expression on inhibition of p38 signal-
ing. Another mechanism may be related to RNA stability,
although a role for p38 in destabilizing specific messages has not
been established. In fact, current evidence from studies on
cyclooxygenase-2 and various cytokines indicates a positive role
for p38 in RNA stabilization (47–49). Finally, the p38 pathway
has also been examined as an inhibitor of other MAPK pathways
(50). Thus, the inhibitory role of p38 may be primarily at the
signaling level, perhaps through activation of a downstream
phosphatase.
Among the pathways tested, the ERK pathway appears to have
a very minor role in early CD40-mediated gene expression. We
know that this pathway does play a role in CD40-mediated B cell
activation because the dose of U0126 used leads to complete
inhibition of CD40-mediated ERK phosphorylation (data not
shown) and also completely inhibits CD40-induced B cell pro-
liferation (Fig. 1B). Although some suggest that ERK is activated
downstream of CD40 in B cells (7), others have suggested that
this may not be the case (4, 5) or that CD40-induced ERK
activation may be more prominent in monocytic cells than in B
cells (51). Our results, based on early gene expression, agree with
the latter hypothesis.
Inhibiting each of these pathways has a profound effect on
CD40-mediated proliferative responses but a much less severe
effect, if any, on CD40-mediated B cell survival. One reason for
this result may be that survival is a less complex response,
requiring the induction of fewer genes. Accordingly, nearly all
CD40-regulated genes with proposed roles in cell death regula-
tion, such as Bcl-x, A1, and A20, are core response genes with
regulation profiles independent of the pathways examined (Fig.
3A). On the other hand, proliferation is most likely a more
complex response requiring the cooperation of multiple path-
ways. For instance, the NF-B pathway regulates the induction
of the oncogenic transcription factor c-myc, which has a docu-
mented role in cellular proliferation (52). The p38 pathway may
contribute by down-regulating the expression of genes, such as
Ndr1, Rb2, and SPA-1 (Fig. 3B), whose expression may nega-
tively regulate growth (37, 38). PI-3K may play a similar role by
down-regulating Rb1 as well as BTG-2, which mediates antipro-
liferative activity through Rb-dependent mechanisms (40).
PI-3K most likely also contributes as a key regulator of a number
of metabolic enzymes and transporters (Fig. 3).
There are three hypothetical mechanisms to account for the
regulation via gene expression of complex biological responses
by multiple signaling pathways downstream of a single receptor.
We call these the independent control, collective control, and
redundant control scenarios for multipathway gene regulation.
In the independent control scenario, each pathway contributes to
the overall gene expression response by regulating a distinct
Fig. 4. Toward a model of B cell activation through CD40-regulated gene
expression. Partially overlapping dependence of CD40-regulated gene subsets
(represented by numbers of pathway-dependent genes in the Venn diagram)
on three major pathways. Small arrows indicate the major contributions of
different pathways to gene up- andor down-regulation. The overall gene
regulation response to CD40 stimulation consists of a number of partially
overlapping gene expression subsets, each depending on a particular path-
way. The partially overlapping nature of these subsets suggests a balance
between independent control (i.e., distinct gene subsets being regulated by
different pathways) and collective control (i.e., a subset of genes whose
regulation depends on all pathways tested). Thus, all pathways contribute to
the regulation of a single group of genes (the collective control cluster),
whereas each pathway also regulates a distinct subset of genes in its inde-
pendent control cluster.
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subset of genes. These different gene subsets then combine to
make up the overall gene expression profile of the stimulus and
cooperatively give rise to its biological effects. In the collective
control scenario, a number of signal transduction pathways
cooperate to regulate a single large set of genes that constitute
the entire gene expression profile. This cooperation may occur
either at the signaling level, via interpathway crosstalk, or at the
transcriptional level, through multicomponent transcriptional
complexes. Finally, in the redundant control situation, different
pathways can substitute for one another in the regulation of each
downstream gene. Thus, the overall expression response remains
intact in the absence of a single pathway. Other work examining
the roles of multiple pathways in growth factor-stimulated
fibroblasts has suggested a high degree of functional redundancy
among pathways, as most gene induction was either unaffected
or broadly affected by different manipulations (i.e., redundant
vs. collective control) (53). We find, as shown in Fig. 3, that there
are some subsets whose regulation fits the independent control
mechanism and other genes that appear to require all or most of
the pathways tested for their regulation (i.e., collective control).
Thus, both the independent and collective mechanisms describe
the response of primary B cells to CD40 activation (Fig. 4).
In summary, we define a mechanism for the cooperation of
multiple signaling pathways in regulating overall early gene
expression downstream of CD40. The NF-B pathway contrib-
utes to primary gene induction, the PI-3K pathway contributes
to gene induction and inhibition, and the p38 pathway contrib-
utes primarily to gene inhibition. The ERK pathway appears to
have little role in early CD40-mediated gene regulation. In
addition, CD40-regulated genes were classified into one of three
categories reflecting their pathway-dependence characteristics:
core response, independent control, and collective control. The
distribution of genes among these categories was roughly bal-
anced, indicating that both independent and collective control
play significant roles in the response of B cells to CD40,
suggesting, in principle, that individual gene subsets downstream
of CD40 can be targeted by manipulating the CD40-mediated
activation of a single signal transduction pathway while leaving
other responses intact.
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